|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
University of Utah |
|---|---|
| Information provided by: | University of Utah |
| ClinicalTrials.gov Identifier: | NCT00420602 |
Purpose
We have found that biomarkers of long-term elevated dietary intake of omega-3 fatty acids such as DHA and EPA are inversely associated with severity of disease phenotype in STGD3 patients. Therefore, the purpose of this study is to follow STGD3 patients as they supplement their diets with DHA/EPA.
| Condition | Intervention |
|---|---|
|
Dominantly Inherited Stargardt's Disease (STGD3) |
Dietary Supplement: Over the counter DHA/EPA dietary supplementation |
| Study Type: | Interventional |
| Study Design: | Prevention, Open Label, Historical Control, Single Group Assignment, Efficacy Study |
| Official Title: | Clinical Interventions Against Stargardt Macular Dystrophy: DHA Supplementation in Patients With STGD3 |
| Estimated Enrollment: | 15 |
| Study Start Date: | August 2006 |
| Estimated Study Completion Date: | August 2009 |
| Estimated Primary Completion Date: | December 2008 (Final data collection date for primary outcome measure) |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| United States, Utah | |
| Moran Eye Center, University of Utah | |
| Salt Lake City, Utah, United States, 84132 | |
| Principal Investigator: | Paul S. Bernstein, MD Ph.D. | University of Utah |
More Information
| Responsible Party: | University of Utah, John Moran Eye Center ( Paul Bernstein, MD, PhD ) |
| Study ID Numbers: | DHA STGD3 |
| Study First Received: | January 10, 2007 |
| Last Updated: | July 23, 2008 |
| ClinicalTrials.gov Identifier: | NCT00420602 History of Changes |
| Health Authority: | United States: Institutional Review Board |
